| Painstop Spine Clinic, Llc | |
|
180 Debuys Rd Biloxi MS 39531-4402 | |
| (228) 273-4096 | |
| (228) 594-1765 |
| Full Name | Painstop Spine Clinic, Llc |
|---|---|
| Speciality | Pain Medicine |
| Location | 180 Debuys Rd, Biloxi, Mississippi |
| Authorized Official Name and Position | Stacey M Tsang (GENERAL MANAGER) |
| Authorized Official Contact | 6265126348 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Painstop Spine Clinic, Llc Po Box 4594 Biloxi MS 39535-4594 Ph: (228) 273-4096 | Painstop Spine Clinic, Llc 180 Debuys Rd Biloxi MS 39531-4402 Ph: (228) 273-4096 |
| NPI Number | 1063715746 |
|---|---|
| Provider Enumeration Date | 12/17/2010 |
| Last Update Date | 01/07/2020 |
| Medicare PECOS PAC ID | 9739355124 |
|---|---|
| Medicare Enrollment ID | O20120106000275 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063715746 | NPI | - | NPPES |
| 30270G0134 | Other | MS | PTAN |
| DT9919 | Other | MS | RAILROAD MEDICARE, GROUP PTAN |
| 00057070 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | (* (Not Available)) | Primary |
| Provider Name | Brian Tsang |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1194819045 PECOS PAC ID: 2163315136 Enrollment ID: I20040204000237 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Gina Gauthreaux |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1639616378 PECOS PAC ID: 8022062686 Enrollment ID: I20050307000242 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Linda C Bell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003014440 PECOS PAC ID: 8820181456 Enrollment ID: I20070912000357 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | April Michelle Ellis |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104263433 PECOS PAC ID: 2769623420 Enrollment ID: I20171019002925 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Veronica Lynn Walker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285287698 PECOS PAC ID: 8820420409 Enrollment ID: I20191120001328 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Susan Brandenburg Pearson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942799796 PECOS PAC ID: 6800225863 Enrollment ID: I20200326003685 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Deena Asfour-mack |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1871120832 PECOS PAC ID: 6204265630 Enrollment ID: I20200406000853 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Courtney Breland Henry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356014880 PECOS PAC ID: 5395130074 Enrollment ID: I20220316000064 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Ramunda Cooper Livingston |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1326780289 PECOS PAC ID: 5395132724 Enrollment ID: I20220503001806 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Keyln E Martin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063145902 PECOS PAC ID: 1759757453 Enrollment ID: I20221020003252 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Shelia Denise Mickle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457073546 PECOS PAC ID: 6901273556 Enrollment ID: I20221110001693 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Tina M Cvitanovich |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1730403429 PECOS PAC ID: 2961876107 Enrollment ID: I20230329003184 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Hannah Marie Smith |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609234970 PECOS PAC ID: 9638473499 Enrollment ID: I20230707001337 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Grace Duff Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336825330 PECOS PAC ID: 4082073952 Enrollment ID: I20230711000050 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | William Xu |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1700153244 PECOS PAC ID: 9436432614 Enrollment ID: I20230727001643 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
| Provider Name | Jennifer Marie Myers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063284933 PECOS PAC ID: 9931552064 Enrollment ID: I20240125000790 |
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
News Archive
Barbara Gilchrest, MD, professor and Chair Emeritus of the department of dermatology at Boston University School of Medicine (BUSM) and dermatologist at Boston Medical Center (BMC), has been named a 2012 Charter Fellow of the National Academy of Inventors (NAI). Gilchrest, a resident of Boston's North End, is among four faculty members at Boston University nominated to the NAI in 2012.
HHS Secretary Kathleen Sebelius today released The National Health Security Strategy, the nation's first comprehensive strategy focused on protecting people's health during a large-scale emergency. The strategy sets priorities for government and non-government activities over the next four years.
Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
BioTime, Inc. announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells.
› Verified 2 days ago
Pass Road Walk-in Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2771 Pass Rd, Suite B, Biloxi, MS 39531 Phone: 228-385-4645 Fax: 228-385-4695 | |
Healthstop Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2490 Pass Rd, Biloxi, MS 39531 Phone: 228-207-9967 Fax: 228-273-1532 | |
Khaled A Rikabi, Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 180 Debuys Rd., 215, Biloxi, MS 39531 Phone: 228-594-6484 Fax: 228-594-6494 | |
Regional Digestive Specialists, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15012 Lemoyne Blvd, Biloxi, MS 39532 Phone: 228-392-5787 Fax: 228-354-9169 | |
Ochsner Mississippi, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2781 C T Switzer Sr Dr Ste 302, Biloxi, MS 39531 Phone: 228-388-4816 Fax: 228-388-5906 | |
Medical Analysis Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1025 Division St, Biloxi, MS 39530 Phone: 228-388-2599 Fax: 228-388-4157 |